TrumpRx claims to offer the lowest prices. But many drugs have cheaper generics
By John Wilkerson, J. Emory Parker, Chelsea Cirruzzo, Elaine Chen, and Daniel Payne,
STAT
| 02. 06. 2026
WASHINGTON — President Trump said his administration’s new TrumpRx website will offer the cheapest prices in the world for 43 brand-name drugs, and counting. But about half of them are already available as generics, usually for much less.
The website is part of the president’s plan to lower drug prices in the U.S. and to counter political attacks by Democrats who have increasingly focused on rising health care costs. Trump unveiled the site on Thursday evening, saying “this launch represents the largest reduction in prescription drug prices in history by many many times, and it’s not even close.”
TrumpRx does not sell medicines directly. Instead, it displays prices available to consumers who pay cash without using insurance, and in some cases directs patients to other sites where they can buy the therapies. The website touts steep discounts for many drugs, compared to their list prices. But an analysis by STAT reveals that’s far from the whole story.
At least 18 brand-name drugs on TrumpRx have cheaper generics available via GoodRx or Mark Cuban’s Cost Plus Drugs. In some cases, consumers...
Related Articles
By Rob Stein, NPR | 04.23.2026
The Food and Drug Administration approved the first gene therapy to restore hearing for people who were born deaf.
The decision, while only immediately affecting people born with a very rare form of genetic deafness, is being hailed as...
By Alfonso Martinez Arias, Nicolas Rivron, and Naomi Moris, BioNews | 04.20.2026
By George Janes, BioNews | 04.20.2026
New regulations in sperm donation are being implemented by Belgium's Federal Agency for Medicines and Health Products (FAMHP), following revelations regarding the use of sperm carrying a cancer-causing mutation, and widespread breaches of donor limits.
In 2025, it...
By Sriparna Roy, Reuters | 04.23.2026
The U.S. Food and Drug Administration has approved Regeneron’s gene therapy for a rare genetic form of deafness, the company said on Thursday.
This approval, granted under the FDA’s new priority voucher program, marks the introduction of the first gene...